Crystal forms of 2-[4-[(2,3,4- trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
The invention provides polymorphs of a compound of Formula (X): The invention also provided pharmaceutical compositions containing polymorphs of the compound and methods treating conditions in a subject by providing polymorphs of the compound.
1. A crystal comprising a Form A polymorph of a compound of Formula (X):
wherein the Form A polymorph has an endothermic peak at about 85.3° C. (±5° C.) and at about 214.6° C. (±5° C.) in a differential scanning calorimetry (DSC) thermogram.
2. The crystal of claim 1 , wherein the crystal comprises a hydrochloride salt of the compound.
3. The crystal of claim 2 , wherein the crystal comprises a hydrated form of the compound.
4. The crystal of claim 3 , wherein the hydrated form of the compound is a monohydrate.
5. The crystal of claim 2 , wherein the crystal comprises a tri-hydrochloride salt of the compound.
6. The crystal of claim 1 , wherein the crystal is substantially free of polymorphs of Form B, Form C, Form D, and Form E.
7. The crystal of claim 1 , wherein the compound has a DSC thermogram substantially in accordance with FIG. 5 .
8. A crystal comprising a Form A polymorph of a compound of Formula (X):
wherein the Form A polymorph exhibits a dehydration at about 25.9° C. to about 150.0° C. with a weight loss of about 3.46% in a thermogravimetric analysis (TGA).
9. The crystal of claim 8 , wherein the crystal comprises a hydrochloride salt of the compound.
10. The crystal of claim 9 , wherein the crystal comprises a hydrated form of the compound.
11. The crystal of claim 10 , wherein the hydrated form of the compound is a monohydrate.
12. The crystal of claim 9 , wherein the crystal comprises a tri-hydrochloride salt of the compound.
13. The crystal of claim 8 , wherein the crystal is substantially free of polymorphs of Form B, Form C, Form D, and Form E.
14. A crystal comprising a Form A polymorph of a compound of Formula (X):
wherein the Form A polymorph has a TGA thermogram substantially in accordance with FIG. 5 .
15. The crystal of claim 14 , wherein the crystal comprises a hydrochloride salt of the compound.
16. The crystal of claim 15 , wherein the crystal comprises a hydrated form of the compound.
17. The crystal of claim 16 , wherein the hydrated form of the compound is a monohydrate.
18. The crystal of claim 15 , wherein the crystal comprises a tri-hydrochloride salt of the compound.
19. The crystal of claim 14 , wherein the crystal is substantially free of polymorphs of Form B, Form C, Form D, and Form E.
20. A crystal comprising a Form A polymorph of a compound of Formula (X):
wherein the Form A polymorph has a DSC thermogram substantially in accordance with FIG. 5 .
21. The crystal of claim 20 , wherein the crystal comprises a hydrochloride salt of the compound.
22. The crystal of claim 21 , wherein the crystal comprises a hydrated form of the compound.
23. The crystal of claim 22 , wherein the hydrated form of the compound is a monohydrate.
24. The crystal of claim 21 , wherein the crystal comprises a tri-hydrochloride salt of the compound.
25. The crystal of claim 21 , wherein the crystal is substantially free of polymorphs of Form B, Form C, Form D, and Form E.